drugset / Trial / NCT02859259
A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
An oral dose in healthy subjects to determine the relative bioavailabilty of BMS-626529 administered as BMS-663068
Timeline
- Start
- 2016-08-12
- Primary completion
- 2016-08-12
- Completion
- 2016-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fostemsavir | Other / unclassified | 150 mg | Oral |
| Subject | Fostemsavir | Other / unclassified | 600 mg | Oral |